November 24, 2016 - By Hazel Jackson
In a analysts note sent to clients and investors on 24 November, equinet AG stated it was upgrading Biotest (ETR:BIO) stock to a Buy. The firm has EUR 18.00 target price per share on BIO’s stock.
Out of 5 analysts covering Biotest (ETR:BIO), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. €100 is the highest target while €16 is the lowest. The €35.30 average target is 110.12% above today’s (€16.8) stock price. Biotest has been the topic of 24 analyst reports since June 26, 2015 according to StockzIntelligence Inc. Equinet upgraded the stock to “Buy” rating in Wednesday, November 2 report. The stock of Biotest AG (ETR:BIO) earned “Hold” rating by Kepler Cheuvreux on Wednesday, November 25. On Wednesday, November 2 the stock rating was upgraded by Kepler Cheuvreux to “Buy”. The firm has “Buy” rating given on Saturday, February 13 by Kepler Cheuvreux. On Wednesday, September 16 the stock rating was upgraded by Kepler Cheuvreux to “Buy”. Hauck & Aufh?user Privatbankiers KGaA upgraded it to “Buy” rating and €100 target price in Friday, June 26 report. The rating was upgraded by Hauck & Aufhäuser Privatbankiers KGaA on Wednesday, October 7 to “Buy”. The firm has “Buy” rating given on Saturday, May 14 by Hauck & Aufhäuser Privatbankiers KGaA. Equinet upgraded it to “Buy” rating and €18 target price in Friday, August 5 report. Kepler Cheuvreux upgraded the stock to “Buy” rating in Wednesday, July 22 report.
About 248 shares traded hands. Biotest AG (ETR:BIO) has risen 21.17% since April 22, 2016 and is uptrending. It has outperformed by 15.76% the S&P500.
Analysts await Bio-Rad Laboratories, Inc. (NYSE:BIO) to report earnings on February, 23. They expect $0.93 EPS, down 44.64% or $0.75 from last year’s $1.68 per share. BIO’s profit will be $27.18M for 46.27 P/E if the $0.93 EPS becomes a reality. After $0.62 actual EPS reported by Bio-Rad Laboratories, Inc. for the previous quarter, Wall Street now forecasts 50.00% EPS growth.
Insitutional Activity: The institutional sentiment increased to 1.08 in 2016 Q2. Its up 0.01, from 1.07 in 2016Q1. The ratio improved, as 20 funds sold all Biotest AG shares owned while 71 reduced positions. 18 funds bought stakes while 79 increased positions. They now own 17.57 million shares or 3.51% less from 18.21 million shares in 2016Q1.
State Street Corporation has 0.01% invested in the company for 555,885 shares. Parametric Portfolio Associate Lc, a Washington-based fund reported 91,094 shares. Analytic Ltd Company holds 11,826 shares or 0.02% of its portfolio. Hbk Ltd Partnership has 1,678 shares for 0% of their US portfolio. Granahan Incorporated Ma holds 1.01% or 193,634 shares in its portfolio. Martin & Tn accumulated 0.31% or 6,665 shares. Moreover, Gabelli Funds Limited Liability Corporation has 0.04% invested in Biotest AG (ETR:BIO) for 47,000 shares. Citadel Advisors Ltd Liability Corp last reported 20,196 shares in the company. Signaturefd Llc accumulated 0% or 20 shares. Ls Inv Advisors Ltd Company has invested 0.01% of its portfolio in Biotest AG (ETR:BIO). Atlanta Capital Mngmt Co L L C has 1.69% invested in the company for 1.77 million shares. Parametrica Limited last reported 0.57% of its portfolio in the stock. Trexquant L P holds 0.08% of its portfolio in Biotest AG (ETR:BIO) for 4,321 shares. Oxford Asset has invested 0.01% of its portfolio in Biotest AG (ETR:BIO). Everpoint Asset Mngmt Limited Com accumulated 0.2% or 70,000 shares.
Insider Transactions: Since June 10, 2016, the stock had 0 buys, and 19 sales for $2.57 million net activity. Crowley Michael sold $81,075 worth of stock. $14,543 worth of Biotest AG (ETR:BIO) shares were sold by Hall Shannon. Shares for $1.03M were sold by SCHWARTZ ALICE N on Friday, June 10. $41,699 worth of shares were sold by STARK JAMES R on Saturday, September 10. Magni Giovanni also sold $14,543 worth of Biotest AG (ETR:BIO) on Monday, September 12. 227 Biotest AG (ETR:BIO) shares with value of $37,596 were sold by HERTIA JOHN.
Biotest AG is a Germany-based biotechnology research and development firm and supplier of biological medicines obtained from human blood plasma or manufactured using biotechnology methods. The company has a market cap of 613.25 million EUR. The Company’s main indication areas are hematology, clinical immunology and intensive care medicine. It has a 198.91 P/E ratio. It operates through three divisions: Therapy, Plasma and Services, and Other.
According to Zacks Investment Research, “Bio-Rad Laboratories, Inc., together with its subsidiaries, engages in the manufacture and supply of products and systems for the life science research, healthcare, analytical chemistry, and other markets worldwide. The company’s products are used to separate complex chemical and biological materials, and to identify, analyze, and purify their components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment offers electrophoresis, image analysis, molecular detection, chromatography, gene transfer, sample preparation, and amplification products and services. The Clinical Diagnostics segment provides control, autoimmune, diabetes, and blood virus testing products. Bio-Rad is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. The company is headquartered in Hercules, California.”
Bio-Rad Laboratories, Inc. (Bio-Rad), incorporated on March 10, 1975, is a maker and distributor of life science research and clinical diagnostics products. The Firm makes and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. Bio-Rad operates in two divisions: Life Science and Clinical Diagnostics. The Company’s Life Science segment develops, makes, sells and services reagents, apparatus and instruments used for biological research. The Company’s Clinical Diagnostics segment develops, makes, sells and services automated test systems, informatics systems, test kits and specialized quality controls for the healthcare market. Bio-Rad sells over 8,000 services and products to a client base consisting of scientific research, healthcare, education and government clients around the world.
More notable recent Biotest AG (ETR:BIO) news were published by: Fiercebiotech.com which released: “News: Biotest AG: Biotest regains rights to Tregalizumab (BT-061)” on June 24, 2015, also Businesswire.com with their article: “EMD Millipore Expands Product Portfolio With Merck KGaA Acquisition of Biotest …” published on March 22, 2011, Prnewswire.com published: “Biotest Pharmaceuticals Corporation Announces the Appointment of Kedrion …” on January 19, 2016. More interesting news about Biotest AG (ETR:BIO) were released by: Reuters.com and their article: “Abbott, Biotest seal deal over arthritis drug” published on June 21, 2011 as well as Prnewswire.com‘s news article titled: “FDA Approves Biotest’s BIVIGAMâ„¢, an Intravenous Immune Globulin (Human), 10 …” with publication date: December 20, 2012.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.